Oncopeptides AB (STU:OND) ROE % Adjusted to Book Value : -42.98% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB ROE % Adjusted to Book Value?

Oncopeptides AB's ROE % for the quarter that ended in Sep. 2024 was -146.13%. Oncopeptides AB's PB Ratio for the quarter that ended in Sep. 2024 was 3.40. Oncopeptides AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -42.98%.

Oncopeptides AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Oncopeptides AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB ROE % Adjusted to Book Value Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-11.61

-127.43

-33.85

-11.28

Oncopeptides AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-17.18	-28.64	-	-98.90	-42.98

Competitive Comparison of Oncopeptides AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oncopeptides AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's ROE % Adjusted to Book Value falls into.

Oncopeptides AB ROE % Adjusted to Book Value Calculation

Oncopeptides AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-139.86%	/	12.40
	=	-11.28%

Oncopeptides AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-146.13%	/	3.40
	=	-42.98%

Oncopeptides AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.